Home

aidsmap HIV & AIDS news

• South Africa exceeds 2007-11 treatment targets by 50%

  New Access to medicines and treatment
  Carole Leach-Lemens | 7 hours ago

  South Africa exceeded national targets for new patients starting antiretroviral treatment (ART) by around 50% between 2007 and 2011 – achieving treatment coverage of close to 80% of eligible adults – according to ...

• US regulators set to approve HIV home-testing kit

  New Types of tests
  Roger Pebody | 23 hours ago

  HIV home testing is soon likely to become legal in the United States, following a unanimous vote in support of the OraQuick In-Home HIV Test by a panel of experts advising the ...

• Standard hepatitis C therapy improves insulin resistance in HIV/hepatitis C co-infected patients

  Hepatitis C treatment
  Michael Carter | 16 May 2012

  Treatment with pegylated interferon and ribavirin is associated with lasting improvements in insulin resistance among HIV-positive people co-infected with hepatitis C, investigators report in the online edition of Clinical Infectious Diseases. Hepatitis C therapy ...

• BI 201335 & BI 207127 and ribavirin shows good efficacy, including hepatitis C patients with cirrhosis

  New and experimental hepatitis C treatment
  Liz Highleyman | 15 May 2012

  An interferon-free regimen of the hepatitis C virus (HCV) protease inhibitor BI 201335, the non-nucleoside polymerase inhibitor BI 207127, and ribavirin produced sustained virological response in 68% of previously untreated genotype 1 hepatitis C ...

• US regulators vote for approval of PrEP by large majority

  PrEP
  Gus Cairns | 11 May 2012

  The US Food and Drug Administration (FDA) took a decisive step yesterday towards approving the use of the combination pill Truvada (tenofovir/FTC) as a prevention method for HIV-negative people.The FDA’s ...

• Canadian cohort shows viral suppression most likely with atazanavir/ritonavir-based HIV treatment after 6 months

  Adherence
  Michael Carter | 11 May 2012

  Antiretroviral therapy based on the ritonavir-boosted protease inhibitor atazanavir (Reyataz) was more likely to achieve virological suppression after six months than treatment containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (Sustiva, also in ...

• Ribavirin dose reduction is effective for managing anaemia in patients using boceprevir or telaprevir

  Hepatitis C treatment
  Liz Highleyman | 11 May 2012

  Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anaemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th ...